GlassScriptPhysician profile
Richard D Smith
NPI 1053350009
$1,894.53
in general payments reported to CMS, 2019-2025
23 companies · $362 in 2025
The $362 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $181 · 2021: $224 · 2022: $303 · 2023: $364 · 2024: $350 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,076.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $454.30 | 2022-2024 | |
| Lilly USA, LLC | $287.45 | 2020-2024 | Mounjaro |
| Novo Nordisk INC | $165.79 | 2019-2025 | Ozempic, Rybelsus |
| Inspire Medical Systems, INC. | $134.96 | 2025 | Inspire |
| Pfizer INC. | $128.35 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $95.62 | 2019-2023 | Verquvo |
| Abbott Laboratories | $80.66 | 2022-2025 | Freestyle Libre 3 |
| Abbvie INC. | $80.29 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $79.69 | 2024-2025 | Keveyis, Gvoke Hypopen |
| Boston Scientific Corporation | $56.20 | 2023-2024 | Watchman Flx, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.22 | 2023-2025 | Jascayd, Jardiance, Spiriva Respimat |
| Novartis Pharmaceuticals Corporation | $43.34 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $40.39 | 2024-2025 | Gemtesa |
| Neurelis, INC. | $28.83 | 2024 | Valtoco |
| Esperion Therapeutics, INC. | $27.96 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.23 | 2025 | Caplyta |
| Arbor Pharmaceuticals, INC. | $21.34 | 2020 | |
| Dynavax Technologies Corporation | $18.39 | 2024 | Heplisav-B |
| Astellas Pharma US INC | $17.27 | 2025 | Veozah |
| Global Blood Therapeutics, INC. | $17.24 | 2022 | |
| Exact Sciences Corporation | $16.28 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.95 | 2019 | |
| Athena Bioscience, LLC | $13.78 | 2023 | Nexiclon Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.